Clinical trials: Covid19 Vaccine
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2)…
- Trial name
- NCT05310084
- Testing
- BNT162b2, Seasonal Inactivated Influenza Vaccine
- Where
- 26 sites in Australia, New Zealand
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Vaccine
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
This is an open-label and non-randomized study to demonstrate the immunogenicity and safety profile in adults that received the Ad5-nCoV vaccine at least 21 days but no later than 90 days after the first dose of Sputnik V.
- Trial name
- FH-63 (NCT05293223)
- Testing
- Ad5-nCov
- Where
- 3 sites in Argentina
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Fundación Huésped
COVID-19, Vaccines
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated.
- Trial name
- COVID-19 (NCT05993325)
- Testing
- AdCLD-CoV19-1 OMI, Comirnaty Bivalent 0.1mg/mL (tozinameran and riltozinameran)
- Where
- 17 sites in Philippines, South Korea
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
COVID-19 Infection, Malignant Solid Neoplasm
Efficacy and Safety of COVID-19 Vaccine in Cancer Patients
This study gathers information about how a cancer patient responds to COVID-19 vaccine during cancer treatment compared to healthy individuals.
- Trial name
- NCT04865133
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Influenza,Human, COVID-19
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed.
- Trial name
- NCT06683352
- Testing
- Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine
- Where
- 22 sites in United States
- Volunteers
- 1,353 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Healthcare Workers, COVID-19
The ESPERES Prospective Cohort of Healthcare Workers in France: Study on COVID-19 Vaccine and the COVID-19 Pandemic (ESPERES_COVID19)
This is the first study performed within the ESPERES cohort, related to prevention against COVID-19, in particular vaccination against COVID-19 and more broadly on the COVID-19 pandemic.
- Trial name
- NCT04844515
- Where
- France
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)
The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by…
- Trial name
- NCT04951323
- Testing
- anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Liege
COVID-19, SARS-CoV-2 Pneumonia
A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years…
- Trial name
- NCT05465785
- Testing
- Recombinant COVID-19 vaccine (Sf9 cell)
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Covid19, Vaccine Reaction
Immunogenicity Against SARS-CoV-2 in COVID-19 Close Contacts
This study will investigate the presence of SARS-CoV-2 neutralizing antibody and its association with demographic information, medical history of SARS-CoV-2 infected individuals, exposure history of close contacts, vaccination…
- Trial name
- NCT05094635
- Testing
- SARS-CoV-2 IgG II Quant
- Where
- Vietnam
- Volunteers
- 772 people
- Sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
Covid19 Vaccination, Vaccine Uptake
Supporting Audit and Feedback to Encourage Vaccine Uptake
In Ontario, approximately 6,000 family physicians can access a secure online system that provides a report that lists the COVID-19 vaccination status for each patient in their roster.
- Trial name
- NCT05099497
- Testing
- Using Practice Facilitators to Support Physicians
- Where
- Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Women's College Hospital
Covid19, Vaccine Refusal
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID…
- Trial name
- NCT04871776
- Testing
- Messaging informed by construal level theory, Usual Care
- Where
- United States
- Volunteers
- 3,671 people
- Sponsor
- Brigham and Women's Hospital
COVID-19
Specimen Collection Study From Coronavirus Disease 2019 (COVID-19) Vaccinated Adults and Adolescents
This is a specimen collection study intended to generate a biological specimen repository of samples from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults and adolescents ≥12 years old who will receive…
- Trial name
- CoVacSpec (NCT05252910)
- Where
- 32 sites in United States, Colombia and 5 more
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pharm-Olam, LLC
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine.
- Trial name
- NCT06291857
- Testing
- CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine
- Where
- 58 sites in Australia, New Zealand
- Volunteers
- 9,320 people, healthy volunteers welcome
- Sponsor
- Novavax
Vaccine Reaction, COVID-19
Determining Reactogenicity and Immunogenicity of Delayed COVID-19 Vaccine Schedule in Children
COVID-19 vaccine response data in children 5 to 11 years old remain scarce. Our understanding of the safety and immune responses including humoral and cellular responses generated in children remains limited.
- Conditions
- Vaccine Reaction, COVID-19, Children, Only
- Trial name
- NCT05329064
- Testing
- BNT162b2 Pfizer-BioNTech/Comirnaty
- Where
- Singapore
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- KK Women's and Children's Hospital
Vaccine Response Impaired, Immune Suppression
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
This study will be a randomized, double-blind, placebo-controlled trial of a third dose of Moderna vaccine versus placebo. Participants will be those that have received two doses of mRNA-1273 COVID vaccine (Moderna) at 0 and 1…
- Conditions
- Vaccine Response Impaired, Immune Suppression, Covid19
- Trial name
- NCT04885907
- Testing
- mRNA-1273 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
COVID-19, SARS-CoV-2
Secondary Databased Post-marketing Surveillance Study of BNT162b2
This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.
- Trial name
- NCT06743334
- Testing
- Tozinameran (BNT162b2), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
- Where
- South Korea
- Volunteers
- 14,302,529 people
- Sponsor
- Pfizer
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as…
- Trial name
- NCT04927065
- Testing
- mRNA-1273.211, mRNA-1273, mRNA-1273.617.2
- Where
- 23 sites in United States
- Volunteers
- 5,161 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)
A total of 300 healthy volunteers between the ages of 18 and 80 with no previous history of COVID-19 will be entered into the study and will receive IPV by injection on Day 1.
- Trial name
- NCT04639375
- Testing
- Vaccinated with polio vaccine (IPV)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- E-MO Biology Inc
Liver Transplant
Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
A prospective cohort study to evaluate the response to COVID-19 vaccine in liver transplantation patients.
- Trial name
- NCT05051605
- Testing
- COVID-19 Vaccine
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
COVID-19
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
This is a retrospective test-negative case-control study of COVID-19 Vaccine (CoronaVac®) manufactured by Sinovac Research and Development Co., Ltd.The main purpose of this study is to measure vaccine effectiveness of homologous…
- Trial name
- NCT05367895
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Brazil
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.